Drug Trial Radar · NCT00709371
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
Last checked: Nov 20, 2026Latest source record: Nov 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
729
Actual
Start
Jul 2008
Primary completion
Apr 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Orexigen Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
Conditions
- Obesity
Interventions
Zonisamide SR placebo/ bupropion SR placeboDrug
2 placebo combination tablets twice daily for 16 weeks (maintenance period)
Zonisamide SR placebo/ bupropion SR 360 mg/dayDrug
2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 120 mg/day/ bupropion SR placeboDrug
2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 360 mg/day/ bupropion SR placeboDrug
2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 120 mg/day/ bupropion SR 360 mg/dayDrug
2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 360 mg/day/ bupropion SR 360 mg/dayDrug
2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in total body weightTime frame: from baseline to 24 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
SelfCenter, PC
Fairhope, Alabama
Nutrition and Metabolic Research
La Jolla, California
Center for Human Nutrition/UCD
Denver, Colorado
Miami Research Associates
Miami, Florida
CSRA Partners in Health, Inc.
Augusta, Georgia
Radiant Research, Chicago
Chicago, Illinois
Welborn Clinic
Evansville, Indiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Nutrition and Weight Management Center, Boston Medical Center
Boston, Massachusetts
FutureCare Studies
Springfield, Massachusetts
Summit Research Network (Michigan), Inc.
Farmington Hills, Michigan
Mercy Health Research
St Louis, Missouri
Center for Nutrition and Metabolic Disorders, University of Nevada School of Medicine
Reno, Nevada
Behavioral Medical Research
Staten Island, New York
Internal Medicine Associates of Charlotte
Charlotte, North Carolina
Wake Research Associates, LLC
Raleigh, North Carolina
Summit Research Network (Oregon), Inc.
Portland, Oregon
The Cooper Institute
Dallas, Texas
Washington Center for Weight Management and Research
Arlington, Virginia
Summit Research Network (Seattle), LLC.
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.